Sign In
Buy RLY
$36.80
-0.110 (-0.298%)
At Close: Jun 03, 2026
Shareholder Alert: Ademi LLP investigates whether Rallybio Corporation is obtaining a Fair Price for Public Shareholders
12:15pm, Tuesday, 02'nd Jun 2026
MILWAUKEE, June 2, 2026 /PRNewswire/ -- Ademi LLP is investigating Rallybio (Nasdaq: RLY) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with
Matt Bartolini Talks Inflation-Resilient Portfolios & More
04:14pm, Friday, 15'th May 2026
With global macroeconomic pressures not abating any time soon, and inflation signals coming in higher than expected, many advisors and investors are seeking guidance on how to amplify inflation protec
ETFs to Navigate the Tech Euphoria and Inflation Collision
01:46pm, Thursday, 14'th May 2026
With the U.S. economy grappling with persistent energy shocks and rising electricity costs, inflation expectations for the next five years have climbed to their highest levels in four years. For finan
SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY) Short Interest Up 142.0% in February
01:30am, Saturday, 14'th Mar 2026
SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY - Get Free Report) was the target of a large growth in short interest in February. As of February 27th, there was short interest totaling 235,641 sh
Persistent Inflation Reignites Case for Real Asset ETFs
03:48pm, Wednesday, 11'th Mar 2026
Given all the ongoing uncertainty over the trajectory of both inflation and the Federal Reserve's rate-cutting regimen, advisors and investors were keen to see what the latest CPI report brought in.
RLY: Tactical ETF Focusing On Natural Resources And Infrastructure
05:28am, Sunday, 08'th Mar 2026
The State Street SPDR SSGA Multi-Asset Real Return ETF targets real returns above inflation via active allocation across inflation-linked assets, real estate, commodities, and infrastructure. RLY's po
Catalyst Financial Partners LLC Has $1.68 Million Stake in SPDR SSgA Multi-Asset Real Return ETF $RLY
04:36am, Thursday, 26'th Feb 2026
Catalyst Financial Partners LLC lifted its position in shares of SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY) by 43.6% in the undefined quarter, according to the company in its most recent For
Thrivent Financial for Lutherans Grows Holdings in SPDR SSgA Multi-Asset Real Return ETF $RLY
04:18am, Sunday, 08'th Feb 2026
Thrivent Financial for Lutherans lifted its position in shares of SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY) by 81.2% in the third quarter, according to the company in its most recent disclo
Thrivent Financial for Lutherans Has $2.16 Million Stake in SPDR SSgA Multi-Asset Real Return ETF $RLY
05:08am, Wednesday, 24'th Dec 2025
Thrivent Financial for Lutherans grew its stake in shares of SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY) by 145.2% in the second quarter, according to its most recent filing with the SEC. The
SPDR SSgA Multi-Asset Real Return ETF $RLY is First International Bank & Trust’s 3rd Largest Position
04:28am, Thursday, 18'th Dec 2025
First International Bank and Trust cut its stake in shares of SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY) by 3.5% during the third quarter, according to its most recent disclosure with the SE
Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with P
SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY) Reaches New 52-Week High – Should You Buy?
02:56am, Sunday, 30'th Nov 2025
SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY - Get Free Report) hit a new 52-week high during trading on Friday. The company traded as high as $31.76 and last traded at $31.7240, with a volume
Multi-Asset ETFs for the Debasement Trade
09:06am, Wednesday, 12'th Nov 2025
The “debasement trade” has been a persistent investment theme this year as the market translates trade disputes, fiscal deficits, rate policy, and geopolitical tension into a negative outlook for
Relay Therapeutics Is A Buy For Its Superb Safety Data
01:21pm, Friday, 24'th Oct 2025
Relay Therapeutics leads with RLY-2608, an allosteric PI3Kα inhibitor showing superior safety and efficacy in advanced breast cancer. RLY-2608's phase 1/2 trial data demonstrates higher response rate
Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer
